Loading ...
Sorry, an error occurred while loading the content.

14082Fw: HCV Advocate Email Alert

Expand Messages
  • Donald Christ
    Jul 31, 2014

      ----- Forwarded Message -----
      From: www.hcvadvocate.org <root@...>
      To: emailalert@...
      Sent: Thursday, July 31, 2014 3:11 PM
      Subject: HCV Advocate Email Alert

      August 1, 2014
      Follow us on


      Join us on Facebook
      Hcvadvocate Hcsp
      Alan Franciscus
      We all hope that you enjoyed the World Hepatitis Day festivities. We are leaving our World Hepatitis Day Wall of Honor up on our ticker tape to view—these are U.S and Canadian advocates who have made a world of difference to the lives of so many with hepatitis C—check our list on our main page. Apologies if we left anyone out—please let us know if we did. There has been lots of news in the world of hepatitis C— check out the information below.
      Alan and the staff of HCV Advocate
      Do you want to stay up to date on the latest news about hepatitis C? Visit our HCV Advocate Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.
      1. HCV Advocate Newsletter: August 2014
      In This Issue:
      Alan Franciscus, Editor-in-Chief
      In this month's HCV Drugs I discuss the approval of Daklinza and Sunpreva in Japan. I am also taking a different look at two of the drugs that will be approved shortly: AbbVie's 3D, and Olysio/Sovaldi, looking at the most common side effects listed in the Phase 3 studies and some of the simple tips to manage them. Lastly, I will discuss the supplemental new drug application for the combination of Olysio and Sovaldi. Read more...
      Lucinda K. Porter, RN
      This month Lucinda talks about one of the horrible consequences of end-stage liver disease—hepatic encephalopathy—what happens when liver disease damages the brain. Read more...
      Patients First
      Alan Franciscus, Editor-in-Chief
      This month I will discuss some of the more serious extrahepatic manifestations of hepatitis C, such as vasculitis, glomerulonephritis, cryoglobulinemia and non-Hodgkin lymphoma and the need for physician awareness of these conditions—especially now that the new treatments are becoming available that can cure hepatitis C in more people, many of whom may have these hepatitis C-related diseases. Read more...
      2. New and Updated Fact Sheets and Guides
      Easy C Side Effect Series:

      PDF Side Effects: Fatigue
      HCV Benefits and Disability Issues:

      PDF Social Security & Disability, by Jacques Chambers, CLU—Social Security offers several types of monthly benefits for a disabled person. Each program has different financial and other eligibility requirements, but they all use the same definition of "disability" to see whether a person is "disabled enough" to qualify for disability benefits. 
      3. HBV Journal Review: August 1, 2014, vol 11, no 8, by Christine Kukka
      In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including the risks of "occult" hepatitis B, tenofovir resistance, treatment disparities, and the safety/efficacy of metformin in cirrhotic patients with diabetes type 2:
      • Health Concerns Grow as Researchers Uncover the Risks of "Occult" Hepatitis B
      • Are Current Hepatitis B Tests Missing Some Infections?
      • First Case of Tenofovir Resistance Found in Patient with Prior Entecavir Resistance
      • Even Specialists Fail to Treat Hepatitis in Patients Who Qualify for Treatment
      • No Benefit Found from Antiviral Treatment after Liver Cancer Surgery
      • Another Study Confirms Success of Sequential Antiviral and Interferon Treatment
      • Snapshot of Hepatitis B in the United States
      • Metformin Safe and Effective in Cirrhotic Patients with Diabetes Type 2
      4. HCV Advocate News & Pipeline Blog!
      Be sure to check out the latest clinical trial postings (Updated July 8, 2014) at the HCV Advocate News & Pipeline Blog. Just click on the links to the drug companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.
      5. Need Help?!
      Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.

      Alan Franciscus
      Executive Director, Hepatitis C Support Project
      Editor-in-Chief, HCV Advocate http://www.hcvadvocate.org/
      Editor-in-Chief, HBV Advocate http://www.hbvadvocate.org/
      Questions and Comments: If you have questions or comments please do not reply to this email. Questions and/or comments can be directed to alanfranciscus@...
      **Unsubscribe Information: To unsubscribe from this list, simply send an e-mail to: listserv@... with nothing in the subject line and the following in the message body: unsubscribe emailalert.
      Make sure that your email address is all lower case.
      emailalert: Make sure your email address is all lower case.

      Follow us on Twitter

    • Show all 35 messages in this topic